Author

M. Villalta

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Gomez· 2 shared A. Hernandez· 2 shared A. Sanchez· 2 shared A. Segura· 2 shared C. Diaz· 2 shared D. Solano· 2 shared E. Corrales-Aguilar· 2 shared E. Segura· 2 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Gomez

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High efficacy of therapeutic equine hyperimmune antibodies against SARS CoV-2 variants of concern

A. Moreira-Soto, M. Arguedas, H. Brenes, W. Bujan, E. Corrales-Aguilar, C. Diaz, A. Echeverri, M. Flores-Diaz, A. Gomez, A. Hernandez, M. Herrera, G. Leon, R. Macaya, A. Khüne, J. A. Molina-Mora, , J. F. Drexler

This study demonstrates that therapeutic equine polyclonal antibodies effectively neutralize SARS-CoV-2 variants of concern.

bioRxiv · Jun 12, 2021 · PreprintMicrobiology

Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19

G. Leon, M. Herrera, M. Vargas, M. Arguedas, A. Sanchez, A. Segura, A. Gomez, G. Solano, E. Corrales-Aguilar, K. Risner, A. Narayanan, C. Bailey, M. Villalta, A. Hernandez, A. Sanchez, , A. Alape

This paper develops and pre-clinically evaluates two equine-derived anti-SARS-CoV-2 polyclonal formulations for potential COVID-19 treatment, showing high neutralizing capacity against SARS-CoV-2 infection.

bioRxiv · Oct 17, 2020 · PreprintMicrobiology